Back to Authors

Bejanin, Alexandre

https://orcid.org/0000-0002-9958-0951

A5087220534 | I123044942

Mayo Clinic

Universitat Autònoma de Barcelona

Citations 14

O2‐08‐01: ANTE‐MORTEM VOLUME LOSS MIRRORS TDP43 STAGING IN NON‐FTLD OLDER ADULTS

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_10 | Pages: No page available

10.1016/j.jalz.2019.06.4493

IC‐04‐02: ANTEMORTEM VOLUME LOSS MIRRORS TDP43 STAGING IN NON‐FTLD OLDER ADULTS

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_1 | Pages: No page available

10.1016/j.jalz.2019.06.4152

Antemortem volume loss mirrors TDP-43 staging in older adults with non-frontotemporal lobar degeneration

Brain | September 4, 2019 | Volume: 142 | Issue: 11 | Pages: 3621-3635

10.1093/brain/awz277 | PMID 31562527

The specific effect of TDP-43 pathology on grey matter volume in individuals without frontotemporal lobar degeneration is unclear. Bejanin et al. reveal a major and independent contribution of TDP-43 to neurodegeneration and shed light on the regional distribution of TDP-43-related atrophy in older adults.
TDP-43 and Alzheimer’s Disease Pathologic Subtype in Non-Amnestic Alzheimer’s Disease Dementia

Journal of Alzheimer’s Disease | July 13, 2018 | Volume: 64 | Issue: 4 | Pages: 1227-1233

10.3233/jad-180169 | PMID 30010126

Background: TDP-43 has been shown to be strongly associated with memory loss, smaller hippocampal volumes, and faster rates of hippocampal atrophy in Alzheimer’s disease (AD) patients with an amnestic presentation. Whether TDP-43 has any clinical or anatomical associations in AD patients with non-amnestic phenotype is unknown. Objective: To determine whether TDP-43 plays a significant role in the clinic-anatomic features of non-amnestic AD. Methods: All cases with pathologically confirmed intermediate-high probability AD from 1996–2012 were identified and retrospectively sub-classified into amnestic versus non-amnestic dementia at the time of presentation. Neurofibrillary tangle counts were performed in those with a non-amnestic presentation using thioflavin-S microscopy in the hippocampus and three neocortical regions, and all cases were subtyped into hippocampal-sparing, limbic-predominant, and typical AD pathology. TDP-43 immunoreactivity was used to assess for the presence of TDP-43. Statistical analyses helped determine whether pathologic subtype or TDP-43 was more strongly associated with clinico-imaging features. Results: Out of 172 pathologically confirmed AD cases, 36 (19%) were classified as non-amnestic. Twenty-five of these 36 (69%) had typical pathology, 0 limbic-predominant pathology, and 11 (31%) hippocampal-sparing pathology. Eleven (44%) of the 25 cases with typical pathology were TDP-43+. Of the 11 cases with hippocampal-sparing pathology, 4 (36%) were TDP-43+. There were no differences in demographic, clinical, or neuroimaging features in those with TDP-43 versus those without except for older age at onset ( p = 0.02) and age at death ( p = 0.02) in those with TDP-43. AD pathological subtype accounted for slightly more of the variances in the neocortex than TDP-43. Conclusion: In non-amnestic AD, we find little evidence that clinical or anatomical features of the disease are related to TDP-43.